Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | CTCX | Stock Option (right to buy) | Award | +9.16K | 9.16K | Jul 14, 2023 | Common Stock | 9.16K | $2.27 | Direct | F1, F4 | |||
transaction | CTCX | Stock Option (right to buy) | Award | +6.15K | 6.15K | Jul 14, 2023 | Common Stock | 6.15K | $2.27 | Direct | F2, F4 | |||
transaction | CTCX | Stock Option (right to buy) | Award | +61.6K | 61.6K | Jul 14, 2023 | Common Stock | 61.6K | $2.11 | Direct | F3, F4 |
Id | Content |
---|---|
F1 | Options to purchase 9,161 shares of common stock of Legacy Carmell (as defined below) granted on July 17, 2020, which vest as follows: 25% vested on July 17, 2021, July 17, 2022 and July 17, 2023 and the remaining 25% becomes vested in 12 equal monthly installments thereafter, subject to continued service through each vesting date. |
F2 | Options to purchase 6,154 shares of common stock of Legacy Carmell granted on February 10, 2021, which vest as follows: 25% vested on February 10, 2022 and February 10, 2023 and the remaining 50% becomes vested in 24 equal monthly installments thereafter, subject to continued service through each vesting date. |
F3 | Options to purchase 61,563 shares of common stock of Legacy Carmell granted on September 23, 2021, which vest as follows: 25% vested on September 23, 2023 and the remaining 75% becomes vested in 36 equal monthly installments thereafter, subject to continued service through each vesting date. |
F4 | On July 14, 2023, Alpha Healthcare Acquisition Corp. III ("ALPA") consummated a business combination (the "Business Combination") by and among ALPA, Candy Merger Sub, Inc., a Delaware Corporation ("Merger Sub") and Carmell Regen Med Corporation, a Delaware corporation ("Legacy Carmell"), ALPA changed its name to "Carmell Therapeutics Corporation" and Merger Sub merged with and into Legacy Carmell. As part of the Business Combination, each Legacy Carmell stock option was exchanged for a stock option to acquire 0.06154 shares of common stock of Carmell Therapeutics Corporation. |